NEW DELHI:Drug firmAstraZeneca Pharmaon Monday said it has received marketing authorisation fromDrug Controller Generalof India forBenralizumabsolution, indicated as an add-on maintenance treatment for severe asthma.AstraZeneca Pharma India Ltdhas received import and market permission in Form CT-20 (marketing authorisation) fromthe Drugs Controller General ofIndia for Benralizumab 30mg/ml solution for injection (Fasenra), the drug firm said in a regulatory filing.
Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
AstraZeneca Pharma said the receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India, subject to the receipt of related statutory approvals and licenses.
Shares of AstraZeneca Pharma India were 1.22 per cent higher at Rs 4,936.05 apiece on BSE.
Download The Economic Times News App to get Daily Market Updates & Live Business News.